vTv Therapeutics Inc.
vTv Therapeutics Inc. (Nasdaq: VTVT) is a late-stage biopharmaceutical company developing orally administered therapies for metabolic and inflammatory diseases. Its lead candidate, cadisegliatin, is a small-molecule, liver-selective glucokinase activator being evaluated as an adjunct to insulin for type 1 diabetes;… From the company’s description.
Over the twelve months to Sep 30, 2026, vTv Therapeutics Inc. reported revenue of $36.84M, up 216600.0% from a year earlier, and a net loss of $7.68M. Its operating margin was −29.8%, and operations used $21.73M in cash. In fiscal 2025, it reported a net loss of $31.08M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What vTv Therapeutics Inc. does
In the company’s own words
vTv Therapeutics Inc. (Nasdaq: VTVT) is a late-stage biopharmaceutical company developing orally administered therapies for metabolic and inflammatory diseases. Its lead candidate, cadisegliatin, is a small-molecule, liver-selective glucokinase activator being evaluated as an adjunct to insulin for type 1 diabetes; the company is also studying it in type 2 diabetes. Its other programs include TTP273, an oral GLP-1 receptor agonist; preclinical RAGE antagonist TTP-RA; and compounds targeting PPAR-delta and the Nrf2/Bach1 pathway. vTv licenses or collaborates on several programs: Newsoara holds global rights to its PDE4 inhibitor HPP737, while Cantex has worldwide rights to azeliragon, a RAGE antagonist. The company’s CATT1 Phase 3 trial evaluates cadisegliatin in 150 people with type 1 diabetes. Across 11 Phase 1 and three Phase 2 trials, more than 500 patients with type 1 or type 2 diabetes have received cadisegliatin. vTv’s business is focused on research and development, with third parties manufacturing clinical drug supplies.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- HIGH POINT, NC
- Fiscal year end
- December
- CIK
- 1641489
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns vTv Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · vTv Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do vTv Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of vTv Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in vTv Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”